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The	Problem
In 2004, more than 20 million people needed treatment for chemical dependency, while less than 10 percent received it. That same year, over one million teens and adults who needed and wanted treatment for a substance abuse problem went 
untreated. More than one-third of these individuals reported cost or insurance barriers 
as impediments to receiving treatment.1   
New research confirms previous studies in finding that significantly higher costs 
and use of medical services are associated with substance abuse disorders and that 
costs decline with treatment. The study, “Medicaid Chemical Dependency Patients in 
a Commercial Health Plan,” was conducted by Lawrence Walter, Lynn Ackerson and 
Steven Allen and funded by the Robert Wood Johnson Foundation. The authors find 
that the initially higher medical utilization and costs decline significantly after entry 
to chemical dependency treatment programs for both Medicaid and non-Medicaid 
patients. It is unlikely that observed cost reductions are driven by a shift from more 
expensive care (e.g., emergency room visits) to outpatient care because both inpatient 
and outpatient visits also declined.
Treatment of Chemical Dependency May 
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POLICY	PERSPECTIVE
CheMiCAlly DepeNDeNT 
iNDiviDUAls MosT 
fReqUeNTly CiTe lACk of 
iNsURANCe CoveRAge oR 
CosT As The ReAsoN foR 
NoT ReCeiviNg TReATMeNT. 
ADDRessiNg This bARRieR 
CoUlD ACTUAlly ResUlT 
iN CosT sAviNgs siNCe 
TReATMeNT foR sUbsTANCe 
AbUse DisoRDeRs MAy 
leAD To loweR MeDiCAl 
CosTs AND UTilizATioN. The 
UNMeT NeeD foR CheMiCAl 
DepeNDeNCy TReATMeNT 
is iMMeNse (90 peRCeNT 
of Those iN NeeD DiDN’T 
ReCeive TReATMeNT iN 2004) 
AND CoUlD ACTUAlly be 
iNflATiNg MeDiCAl CosTs 
AND UTilizATioN. sTATes (AND 
MANAgeD CARe pRogRAMs) 
gRAppliNg wiTh RisiNg 
MeDiCAiD expeNDiTURes 
shoUlD CoNsiDeR 
MeAsURes To iNCReAse 
ACCess To AND UTilizATioN 
of TReATMeNT pRogRAMs. 
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Treatment of Persons Aged 12 or Older Who Needed Treatment for 
an Alcohol or Illicit Drug Use Problem in 20041
Persons who
did not receive
treatment 
(90.1%)
Persons receiving
treatment at a
specialty facility 
(9.9%)
Source: “Overview of Findings from the 2004 National Survey on Drug Use and 
Health” revisions as of 9/8/2005, from Department of Health and Human Services
The	Facts
Patients’ medical costs decreased by 30 percent on average between the year prior 
to treatment intake and the third year following intake.2 Both Medicaid and non-
Medicaid patients showed average declines of 30 percent in medical costs from the 
baseline period to the third year following treatment initiation. 
Cost trends reflect declines in the use of hospital days, emergency department 
visits and outpatient visits. Both the Medicaid and non-Medicaid patients 
demonstrated declines in all types of visits, while a comparison group (that did not 
show evidence of chemical dependency problems) experienced no such declines.
Between 2003 and 2004, cost or lack of insurance was the most common reason 
for not receiving treatment. Among those who made an unsuccessful effort to get 
treatment, over 40 percent reported cost or insurance barriers as the reason for not 
receiving care.1
—Lauren Necochea
Lauren Necochea, M.P.A., is a Princeton-Robert Wood Johnson Foundation Policy Analyst.
Source: “Overview of Findings from the 2004 National Survey on Drug Use and Health” revisions as of 9/8/2005,  
from Department of Health and Human Services.
Medical costs excluding those directly related to treatment.
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Medical Costs by Patient Type2
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